Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10253447 | 0.89 | CNR2 (0.78) | CNR2MAPTCNR1EPHX2KDM4E | |
| SCHEMBL10253332 | 0.85 | CNR2 (0.80) | CNR2MAPTCNR1EPHX2KDM4E | |
| SCHEMBL4559682 | 0.82 | MAPT (0.73) | CNR2MAPTCNR1EPHX2KDM4E | |
| SCHEMBL14934356 | 0.79 | EPHX2 (0.76) | CNR2EPHX2 | |
| SCHEMBL14306236 | 0.79 | MAPT (0.69) | CNR2MAPTCNR1EPHX2TRPV1 | |
| SCHEMBL10253368 | 0.78 | CNR2 (1.00) | CNR2MAPTCNR1PKMTRPV1 | |
| SCHEMBL6153200 | 0.78 | KMT2A (0.69) | CNR2MAPTCNR1EPHX2TRPV1 | |
| SCHEMBL10253649 | 0.77 | CNR2 (0.84) | CNR2MAPTCNR1EPHX2 | |
| SCHEMBL10253343 | 0.77 | CNR2 (1.00) | CNR2MAPTCNR1EPHX2PKM | |
| SCHEMBL14934436 | 0.76 | EPHX2 (0.76) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885MAPT 3811/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.